Annovis Bio, Inc. (ANVS) · Oct 19, 2026 · Other events

Annovis audit fee correction fixes proxy typo, adds no new risk

Audit fees corrected — 2025 total fees $515,000 vs $482,045 in 2024

Annovis corrected a proxy-statement typo in its audit-fee disclosure. The filing changes reported fees, not the company’s clinical or funding story.

Annovis is a Phase 3 biotech advancing buntanetap for Alzheimer’s and Parkinson’s disease, with the business story centered on late-stage clinical development rather than operating revenue. This filing is administrative, not strategic. The company corrected a typographical error in its June 17, 2026 proxy statement; it does not change the drug program, financing position, trial timeline, or governance. 〔0〕

Fee category20252024
Audit fees$415,000$375,000
Audit-related fees$100,000$107,045
Total fees$515,000$482,045

The corrected numbers show a modest year-over-year increase in total auditor fees, driven by higher audit fees but partly offset by lower audit-related fees (Corrected audit-fee table). There is no meaningful market benchmark or new expectation to beat here; this is a confirmation of corrected historical disclosure, not a new operating signal.

Bottom line: This filing cleans up the proxy record and leaves Annovis’s core clinical-development story unchanged. It is routine housekeeping, not a business catalyst or setback.icar

Original filing on SEC EDGAR

More Annovis Bio, Inc. news

Annovis audit fee correction fixes proxy typo, adds no new risk | ANVS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.